Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
10
pubmed:dateCreated
2000-10-10
pubmed:abstractText
Findings for 41 patients with non-Hodgkin's lymphoma (NHL) treated with high-dose chemotherapy (HDC) and/or autologous peripheral blood stem cell transplantation (PBSCT) are reported. Two of the 41 patients were treated with HDC alone without PBSCT. At transplant, 20 patients were in complete remission, while 19 had resistant NHL and had failed to achieve a complete remission (CR) after several courses of conventional chemotherapy. The conditioning regimens used were mainly ACE (cytarabine, cyclophosphamide, etoposide) and MEAC (MCNU, etoposide, cytarabine, cyclophosphamide). The treatment-related mortality rate was 4.9%. Two patients treated with MEAC died from intractable congestive heart failure. Nine of the 19 patients with resistant NHL achieved CR, and at a median follow-up of 26 months (range, 3 to 93 months) the estimated two-year disease-free survival rate for these patients was 44.4%. Four patients in CR at present were in partial remission before HDC and PBSCT. Fifteen of the 20 patients in CR before HDC were transplanted in first CR and 5 in 2nd CR. At a median follow-up of 49 months (range, 3 to 96 months), the estimated 3-year DFS for the group of all patients was 73.7%. Five relapses occurred between 5 and 35 months post-transplantation. In conclusion, HDC and PBSCT as induction therapy was only effective for patients with resistant NHL who responded to conventional chemotherapy, and may improve the survival of patients in CR as consolidation therapy.
pubmed:language
jpn
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0385-0684
pubmed:author
pubmed:issnType
Print
pubmed:volume
27
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
1547-55
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:11016000-Adolescent, pubmed-meshheading:11016000-Adult, pubmed-meshheading:11016000-Antineoplastic Combined Chemotherapy Protocols, pubmed-meshheading:11016000-Cyclophosphamide, pubmed-meshheading:11016000-Cytarabine, pubmed-meshheading:11016000-Doxorubicin, pubmed-meshheading:11016000-Drug Administration Schedule, pubmed-meshheading:11016000-Etoposide, pubmed-meshheading:11016000-Female, pubmed-meshheading:11016000-Hematopoietic Stem Cell Transplantation, pubmed-meshheading:11016000-Humans, pubmed-meshheading:11016000-Lymphoma, Non-Hodgkin, pubmed-meshheading:11016000-Male, pubmed-meshheading:11016000-Middle Aged, pubmed-meshheading:11016000-Nitrosourea Compounds, pubmed-meshheading:11016000-Prednisone, pubmed-meshheading:11016000-Survival Rate, pubmed-meshheading:11016000-Vincristine
pubmed:year
2000
pubmed:articleTitle
[High-dose chemotherapy with autologous peripheral blood stem cell transplantation for treatment of non-Hodgkin's lymphoma].
pubmed:affiliation
Dept. of Clinical Hematology, Osaka City University.
pubmed:publicationType
Journal Article, Clinical Trial, English Abstract